Personalized Drug Response Profiling for Patient-Derived CLL cells via Miniaturized Gene Expression and Drug Sensitivity Testing on Droplet Microarray
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Karlsruhe, Karlsruher Institut für Technologie (KIT), Dissertation, 2024
- Schlagwort
-
Krebs
- Ereignis
-
Veröffentlichung
- (wo)
-
Karlsruhe
- (wer)
-
KIT-Bibliothek
- (wann)
-
2025
- Urheber
-
El Khaled El Faraj, Razan
- Beteiligte Personen und Organisationen
-
Levkin, Pavel A. A.
Hilbert, Lennart
- DOI
-
10.5445/IR/1000178982
- URN
-
urn:nbn:de:101:1-2502260402033.591543242658
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- El Khaled El Faraj, Razan
- Levkin, Pavel A. A.
- Hilbert, Lennart
- KIT-Bibliothek
Entstanden
- 2025
Ähnliche Objekte (12)
DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery
Miniaturized Drug Discovery Assays Targeting Macrophages in Fibrotic Diseases
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Multiplexed combinatorial drug screening using droplet-based microfluidics
Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL
Drug interactions and response in patient-derived colorectal cancer organoids
Patient-derived xenografts: a relevant preclinical model for drug development
In vitro drug testing using patient-derived ovarian cancer organoids
Drug dosage for microneedle-based transdermal drug delivery systems utilizing evaporation-induced droplet transport
In silico modeling predicts drug sensitivity of patient-derived cancer cells
Correction: In vitro drug testing using patient-derived ovarian cancer organoids
Droplet‐Microarray: Miniaturized Platform for High‐Throughput Screening of Antimicrobial Compounds
DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery
Miniaturized Drug Discovery Assays Targeting Macrophages in Fibrotic Diseases
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Multiplexed combinatorial drug screening using droplet-based microfluidics
Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL
Drug interactions and response in patient-derived colorectal cancer organoids
Patient-derived xenografts: a relevant preclinical model for drug development
In vitro drug testing using patient-derived ovarian cancer organoids
Drug dosage for microneedle-based transdermal drug delivery systems utilizing evaporation-induced droplet transport
In silico modeling predicts drug sensitivity of patient-derived cancer cells
Correction: In vitro drug testing using patient-derived ovarian cancer organoids
Droplet‐Microarray: Miniaturized Platform for High‐Throughput Screening of Antimicrobial Compounds
DRUG-seq for miniaturized high-throughput transcriptome profiling in drug discovery
Miniaturized Drug Discovery Assays Targeting Macrophages in Fibrotic Diseases
Repurposing FDA‐Approved Drugs for Temozolomide‐Resistant IDH1 Mutant Glioma Using High‐Throughput Miniaturized Screening on Droplet Microarray Chip
Multiplexed combinatorial drug screening using droplet-based microfluidics
Drug‐microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL
Drug interactions and response in patient-derived colorectal cancer organoids
Patient-derived xenografts: a relevant preclinical model for drug development
In vitro drug testing using patient-derived ovarian cancer organoids
Drug dosage for microneedle-based transdermal drug delivery systems utilizing evaporation-induced droplet transport
In silico modeling predicts drug sensitivity of patient-derived cancer cells
Correction: In vitro drug testing using patient-derived ovarian cancer organoids